MAPT and Alzheimer disease: Specifically, the biochemical diagnosis of AD relies on the detection of a CSF biomarker profile characterized by the decrease of amyloid beta 1-42 (Aβ 1-42), the ratio Aβ 1-42/1-40 and the increase of t-Tau and p-Tau levels [13].